NitraTh epitope-based neoantigen vaccines for effective tumor immunotherapy
Cancer Immunology, Immunotherapy · 2024
DOI: 10.1007/s00262-024-03830-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Wanli Zhang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Druggability of Biopharmaceuticals and State Key Laboratory of Natural Medicines, School of Life Science and Technology, Ch…. Hauptthemen laut MEDLINE: Cancer Vaccines, Immunotherapy, Antigens, Neoplasm. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, the Key R&D Program of Xinjiang Uygur Autonomous Region.
Abstract (Originalsprache)
Neoantigen vaccines represent an emerging and promising strategy in the field of tumor immunotherapy. Despite their potential, designing an effective neoantigen vaccine remains a challenge due to the current limitations in predicting CD4+ T cell epitopes with high accuracy. Here, we introduce a novel approach to neoantigen vaccine design that does not rely on computational prediction of CD4+ T cell epitopes. Utilizing nitrated helper T cell epitope containing p-nitrophenylalanine, termed "NitraTh epitope," we have successfully engineered a series of tumor neoantigen vaccines capable of eliciting robust neoantigen-specific immune responses. With the help of NitraTh epitope, even mutations with low predicted affinity for MHC class I molecules were successfully induced to elicit neoantigen-specific responses. In H22 cell allograft and patient-derived xenograft (PDX) liver cancer mouse models, the NitraTh epitope-based neoantigen vaccines significantly suppressed tumor progression. More strikingly, through single-cell sequencing we found that the NitraTh epitope-based neoantigen vaccines regulate macrophage reprogramming and modulate macrophages to decrease the levels of the immunosuppressive molecule prostaglandin E2 (PGE2), which in turn reshapes the tumor immunosuppressive microenvironment. In summary, NitraTh epitope-based neoantigen vaccines possess the dual effects of potently activating neoantigen-specific immunity and alleviating immunosuppression, potentially providing a new paradigm for the design of tumor neoantigen vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Laboratory of Druggability of Biopharmaceuticals and State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, 211198, People's Republic of C…
- Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, People's Republic of Chin…
- Department of Neurosurgery, The First People's Hospital of Changzhou, Changzhou, 213003, Jiangsu, People's Republic of China.
Förderung
- National Natural Science Foundation of China
- the Key R&D Program of Xinjiang Uygur Autonomous Region
Zitieren
APA
Zhang, W., Shi, X., Huang, S., Yu, Q., Wu, Z., Xie, W., Li, B., Xu, Y., Gao, Z., Li, G., Qian, Q., He, T., Zheng, J., Zhang, T., Tong, Y., Deng, D., Gao, X., Tian, H., & Yao, W. (2024). NitraTh epitope-based neoantigen vaccines for effective tumor immunotherapy. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03830-2
Vancouver
Zhang W, Shi X, Huang S, Yu Q, Wu Z, Xie W, et al. NitraTh epitope-based neoantigen vaccines for effective tumor immunotherapy. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03830-2
BibTeX
@article{Zhang2024,
author = {Zhang, Wanli and Shi, Xupeiyao and Huang, Shitong and Yu, Qiumin and Wu, Zijie and Xie, Wenbin and Li, Binghua and Xu, Yanchao and Gao, Zheng and Li, Guozhi and Qian, Qianqian and He, Tiandi and Zheng, Jiaxue and Zhang, Tingran and Tong, Yue and Deng, Danni and Gao, Xiangdong and Tian, Hong and Yao, Wenbing},
title = {NitraTh epitope-based neoantigen vaccines for effective tumor immunotherapy},
journal = {Cancer Immunology, Immunotherapy},
year = {2024},
doi = {10.1007/s00262-024-03830-2}
}
EUVIMED